CD8A and neoplasm: Adding MEKi to BRAFi also increases CD8+ and CD4+ TILs (Homet Moreno, Mok, Comin-Anduix, Hu-Lieskovan, & Ribas, 2016); anti-tumor responses mediated by this combination are T-cell dependent (Erkes et al., 2020).